For most solid tumors, including melanoma, the most powerful predictor of recurrence and survival is the presence or absence of regional lymph node metastases. For patients with melanoma and stage III disease, the five-year survival decreases 40% compared to patients without nodal metastases. With the approval of interferon alfa-2b as the first effective adjuvant therapy for the high risk for recurrence melanoma population, one can argue that patients with a defined rate of nodal metastases (tumor thickness >1 mm) should have a nodal staging procedure as part of their primary therapy. Lymphatic mapping with sentinel lymph node (SLN) biopsy is the least morbid method to obtain this information.
Routine pathologic examination of the lymph nodes in patients with melanoma examines less than 1% of the submitted material and will underestimate the number of patients with nodal metastases by 25%. The sensitivity of the routine examination is the ability to identify one abnormal melanoma cell in a background of 10 4 normal lymphocytes.
When used routinely, special immunohistochemical staining, such as the S-100 and HMB-45 stain, will increase the sensitivity of the occult metastases examination to identify one abnormal cell in a background of 10 5 lymphocytes.
Molecular biology assays for submicroscopic metastases have been proposed to increase the sensitivity of the regional nodal examination and provide a more accurate staging for the melanoma patient. Lymphatic mapping protocols allow for this more detailed examination by identifying one or two nodes most likely to harbor metastases.
Reverse transcriptase polymerase chain reaction (RT-PCR) assays to detect tyrosinase mRNA have been used as markers for submicroscopic metastases to the sentinel lymph node (SLN). The sensitivity of this assay is the ability to identify one melanoma cell in a background of 10 6 lymphocytes, two orders of magnitude greater in sensitivity than that of the routine examination.
A study conducted at our institute included 114 patients with clinical stage I and II melanoma who had their SLNs harvested (Table) . They were followed for 6 to 48 months (mean = 28 months) for recurrence. Of these 114 patients, 23 (20.2%) had histologic-positive (histo+) SLNs. All of these SLNs were also PCR positive (PCR+ RT -PCR assays for occult metastases based on tyrosinase probes improve the prediction of melanoma recurrence over routine histologic examination, suggesting clinical correlation for the assay. The value of this assay as a prognostic factor for melanoma is being tested in a national multicenter study. 
Eastern Cooperative Oncology Group (ECOG) Trial 1684
In the ECOG trial E1684, 287 patients with deep primary disease (T4, AJCC stage IIB) or regional lymph node metastatic disease (N1, AJCC stage III) were randomized to interferon-alfa (IFN-alpha) treatment or observation between 1984 and 1990. All patients underwent wide excision of the primary tumor and therapeutic or elective lymph node dissection (ELND) prior to entry. They were identified as high-risk by virtue of either pathologically proven lymph node involvement (89%) or deep primary tumor invasion when ELND was negative (11%). Treatment was given in two phases: (1) induction (IFN-alpha2b at 20 million units [MU]/m 2 per day intravenously five days a week for four weeks), followed by (2) maintenance (10 MU/m 2 per day subcutaneously three days a week for the next 48 weeks).
At 7 years of follow-up, the increases in median survival from 2.8 to 3.8 years and in relapse-free interval from 1 to 1.7 years were both statistically significant (P=0.02 and P=0.002, respectively). The benefit was most pronounced among the 249 stage III patients (89% of the study population; P=0.006 for overall survival and P=0.0006 for relapsefree survival). 3 This landmark trial was the pivotal study accepted by the Food and Drug Administration's Oncologic Drug Advisory Committee in its recommendation to approve licensure for IFN-alpha2b (Intron A), as the first adjuvant therapy of melanoma following surgical resection in patients with stage IIB or stage III melanoma. 4 This treatment regimen had substantial toxicity, and grade 3 (ECOG toxicity scale) events were noted at least once in the majority of recipients. Dose modification or delays were required at least once in 50% of patients during the intravenous induction phase and in 48% of patients during the subcutaneous maintenance phase. Most treatment delays occurred in the first four months of the regimen. Concerns regarding the impact of this therapy on quality of life were evaluated in a retrospective quality-of -life (QTWiST) study. 5 After 84 months of follow-up, patients in the IFN-alpha2b arm gained a mean of 8.9 months without relapse (P=0.03) and 7 months of overall survival time (P=0.02) compared to the observation group. The treated group experienced severe treatment-related toxicity for an average of 5.8 months. The net result was that the group treated with IFN-alpha2b had more quality-of -life-adjusted survival time than did the observation group, regardless of the relative valuations placed on time with toxicity and time with relapse.
An economic analysis of the E1684 regimen was recently published by Hillner et al. 6 The projected incremental cost in 1996 US dollars per life-year gained in the IFN cohort of patients ranged from $13,700 after 35 years to $32,600 at seven years (the median follow-up of E1684). The benefits of IFN projected over a lifetime yield incremental cost per life-year or quality-adjusted life-year were both less than $16,000, which compares favorably with the rigorous Canadian benchmark of $20,000 per quality-of -life-year gained and other accepted adjuvant therapies of breast and colorectal cancer.
Intergroup Trial ECOG 1690
This trial was initiated in 1990 before the results of the E1684 trial were mature. This randomized three-arm study compared the same high-dose regimen of IFN-alpha2b described above to the World Health Organization (WHO) low-dose regimen of IFN-alpha2b 3 MU subcutaneously three times per week compared to observation. Targeted accrual of 642 patients was completed in June 1995, and preliminary data analysis was performed in September 1998. A significant impact in relapse-free but not overall survival was seen for the high-dose IFN-alpha arm compared to observation. No impact in either relapse-free or overall survival was seen for the low-dose arm. Further analysis of these preliminary results is awaited. times per week intramuscularly or to observation. Approximately 50% of the patients had clinically node-negative (stage II) disease. Analysis at maturity in 1995 revealed no significant impact on overall or relapse-free survival, but a trend-to-benefit was noted among the patients with clinical stage III disease. 7 The WHO Melanoma Programme trial 16 tested a low-dose regimen of IFN-alpha2a 3 MU given subcutaneously three times per week for three years in 444 patients with recurrent nodal disease. This study was preliminarily reported in a subset analysis at 22 months of median follow-up, suggesting a relapse-free interval prolongation among women younger than 50 years and men older than 50 years. 8 However, later presentations of this study at 39 months or more of follow-up have not continued to suggest durable antitumor activity, in terms of either overall survival or relapse-free interval. 9 The European Organization for Research on Treatment of Cancer (EORTC) has recently commenced a study (18-952) testing the impact on relapse-free interval and survival of intermediate dosages of IFN-alpha2b administered over one or two years compared to observation. The induction phase of this trial is a flat dose of 10 MU subcutaneously five days per week for four weeks followed by a maintenance phase of either 10 MU subcutaneously three times per week for one year or 5 MU subcutaneously three times per week for two years. This study will accrue 1,000 patients with high-risk resected melanoma, including patients with nodal disease with or without extracapsular extension.
Other Trials

Interferon-alfa in the Adjuvant Therapy of Stage IIA Disease
Patients with T3 melanoma (Breslow depth 1.5 to 4 mm, stage IIA) comprise a substantial number of individuals with five-and 10-year survivals of 72.5% and 62%, respectively, for the group as a whole. Thirty-one percent of all newly diagnosed patients with melanoma fall into this category. Given the projected 1998 melanoma incidence of 40,300 cases, approximately 12,400 new cases of stage IIA melanoma will occur and at least 3,400 of these people will die of their disease. An effective adjuvant therapy for this patient population would be of major importance, yet most adjuvant therapy trials for high-risk melanoma have excluded patients with stage IIA melanoma.
The French Cooperative Group on Melanoma recently reported the updated results of a low-dose IFN-alpha trial in stage II (A and B) patients. 10 Eligible patients had surgically resected melanoma without clinical evidence of regional lymph node involvement. Patients were randomized to IFN-alpha2a 3 MU given subcutaneously three times per week for 18 months or to observation. While a preliminary report at less than two years of follow-up was encouraging, a follow-up at three years demonstrated no overall durable survival advantage.
A recently initiated study to be conducted by ECOG (E1697) and the National Cancer Institute of Canada is the only trial to specifically address the issue of adjuvant IFNalpha2b for stage IIA patients. Patients will be randomized to either the induction phase of E1684 (20 MU/m 2 , Monday through Friday for four weeks) or to observation. A total of 1,420 patients are expected to accrue over a two-to three-year period to detect a 7% increase in survival.
Vaccines in the Adjuvant Therapy of Melanoma
The Nearly 30% of patients with melanoma develop metastatic disease (stage IV) requiring systemic therapy. A complete staging is needed to determine the sites of metastases, which most frequently involve skin, lymph nodes, lung, liver, and brain. Since patients with brain metastases require specialized care and may not be candidates for systemic therapy, magnetic resonance imaging of the brain is recommended prior to initiation of systemic therapy.
Options of systemic therapy for patients with stage IV melanoma if they are not candidates for surgical resection (which may be a consideration for isolated metastases in brain, bowel, or lungs) include the following: chemotherapy, interferon-alfa (IFN-alpha2a or IFN-alpha2b), Interleukin-2 (IL-2), and investigational therapy (new drugs, melanoma vaccines). Although dacarbazine (DTIC) alone has been the most commonly used chemotherapy for the treatment of melanoma, other drugs -especially cisplatin and carmustine (BCNU) -have significant activity and are increasingly used in combination. Several combination chemotherapy regimens used during the past two decades have often produced a modest increase in the response rates over that expected from DTIC, although their impact on increasing the survival is still debated. Our efforts in the development of treatment for metastatic melanoma are summarized below.
Cisplatin, Vinblastine, and DTIC
The three-drug regimen containing cisplatin, vinblastine, and DTIC (CVD) was tested in 1986 to 1987. 1 The combination produced a response rate of 40%, which is twofold higher than that of DTIC alone and is comparable to the activity of Dartmouth regimen (cisplatin, BCNU, DTIC, and tamoxifen).
Interferon-alfa
In our experience, IFN-alpha demonstrated a modest response rate of 10% but produced some durable complete responses (CRs). Moreover, IFN-alpha was equally active in chemoresistant disease, indicating lack of cross-resistance with chemotherapy.
